Comparative Pharmacology
Head-to-head clinical analysis: CYMBALTA versus DRIZALMA SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYMBALTA versus DRIZALMA SPRINKLE.
CYMBALTA vs DRIZALMA SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
Selective serotonin reuptake inhibition, resulting in increased synaptic serotonin concentrations and enhanced serotonergic neurotransmission.
60 mg orally once daily, without regard to meals; some patients may benefit from a starting dose of 30 mg once daily for 1 week before increasing to 60 mg once daily.
60 mg orally once daily, with or without food. Capsules may be swallowed whole or opened and sprinkled onto applesauce.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8–17 hours); supports once-daily dosing with consistent drug levels.
12-15 hours; steady-state achieved in 2-3 days; no significant accumulation with q12h dosing.
Renal: approximately 70% as metabolites (duloxetine glucuronide conjugates and sulfate conjugates), 20% as unchanged drug in urine; fecal: approximately 20% as metabolites; biliary: minor contribution.
Primarily renal (approx. 70% as unchanged drug and metabolites); 30% fecal/biliary.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant